NASH can be a silent, slowly progressing disease. It is often diagnosed incidentally and left untreated and can lead to life-threatening cardiovascular co-morbidities.1-2
The NASH Education Program, a GENFIT initiative, exists to raise awareness around NASH and NAFLD by providing information and background on the many aspects of these conditions including disease state, prevalence, risk factors, diagnosis, and treatment.
While GENFIT is broadly dedicated to the development of diagnostic solutions and medical advancement in the metabolic and liver space, GENFIT also developed a patient-centric approach through awareness and education. The NASH Education Program focuses more narrowly on disseminating educational information to healthcare professionals and the public to better inform and educate around our current diagnostic and therapeutic landscape.
DRIVE SCIENTIFIC EDUCATION ABOUT NASH
Before you can see NASH, you must know what you’re looking for. The NASH Education Program carries out both communication and education initiatives with the goal of laying the groundwork for better diagnosis, management, and treatment outcomes for NASH patients.
DRAW ATTENTION TO A MASSIVE PUBLIC HEALTH ISSUE
NASH prevalence is on the rise, even among the pediatric population.3,4 Yet because most symptoms go undetected until the disease has progressed to very late stages, NASH remains poorly understood and under-diagnosed. Awareness and education can help us change the course of this silent epidemic.
IDENTIFY AND ADDRESS UNMET NEED
To help usher in a new treatment landscape, we have launched initiatives to better identify the unique needs of NASH patients and physicians. Our series of targeted surveys through our NASH Global Health ObservatoryTM is helping us clarify the needs of diverse groups through the NASH community so we can begin the work of addressing those needs.
ENCOURAGE COLLABORATION ACROSS DISCIPLINES
Given the tremendous needs related to disease awareness in this new therapeutic area, The NASH Education Program is collaborating with all key stakeholders who are committed to improving NASH patient care, from patient associations and academic organizations to healthcare and life sciences companies.
The NASH Education Program supports everyone in need of understanding the causes, mechanisms, and consequences of the disease to better manage its progression. That includes all medical specialties, hepato-gastroenterologists, diabetologists, endocrinologists, obesity specialists, cardiologists, as well as general practitioners and obstetrician-gynecologists. All have a key role to play in the clinical management of NASH.
In addition, The NASH Education Program supports current patients and their families, as well as individuals at risk and the broader community. By increasing awareness both inside and outside the NASH community, we aim to increase the odds of early diagnosis and appropriate care.
The NASH Education Program brings together an international scientific committee spearheaded by high-profile experts in the NASH field.
To improve NASH outcomes, physicians need to know what they’re looking for. We believe education is the key to properly addressing unmet needs in the NASH community.
Healthcare providers, patients, at-risk individuals, as well as families and advocates deserve access to the latest scientific and medical insights around NASH.
Through education and awareness, we aim to make a real difference in the clinical management of NASH patients by improving patient care.
- Torres DM, Williams CD, Harrison SA, et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastro Hepatol. 2012;10:837-858.
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD- EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016;64(6):1388-1402.
- Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
- Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2013;162(3):496-500.